Yahoo Web Search

Search results

1. sciencebasedmedicine.org › a-critical-look-at-theConclusions Not So NICE: A Critical Analysis of the NICE ...

   sciencebasedmedicine.org › a-critical-look-at-the

   • Cached

   Oct 17, 2021 · The NICE Review of gonadotropin-releasing hormone analogues (GnRHa), medications that block the production of the sex hormones testosterone and estrogen and are used to treat gender dysphoria in adolescents, was published in March 2021. The review included nine observational studies published no later than October 14, 2020: five retrospective studies, three prospective longitudinal studies ...

2. segm.org › sites › defaultEvidence review: Gonadotrophin releasing hormone analogues ...

   segm.org › sites › default

   clinical effectiveness, safety and cost-effectiveness of gonadotrophin releasing hormone (GnRH) analogues for children and adolescents aged 18 years or under with gender dysphoria. The document was prepared by NICE in October 2020. The content of this evidence review was up to date on 14 October 2020. See summaries of

3. Videos

   • 

     3:30

     youtube.com

     5 Common Side Effects Of Hormone Replacement Therapy (HRT) | Maryon Stewart

     17 Jan 2018

     18.2K views

   • 

     1:06

     youtube.com

     Considering hormone replacement therapy (HRT)? Here’s what you should know - Online interview

     27 Jun 2022

     1.2K views

   • 

     7:53

     youtube.com

     My Experience with Hormone Replacement Therapy (HRT) for Menopause | Tamsen Fadal

     23 Mar 2022

     16.7K views

   View all

4. www.bbc.com › news › health-56601386Evidence for puberty blockers use very low, says NICE - BBC

   www.bbc.com › news › health-56601386

   • Cached

   Apr 1, 2021 · Puberty blockers, known scientifically as gonadotrophin-releasing hormone (GnRH) analogues, are prescribed to some young people with gender dysphoria - distress caused by a discrepancy between a ...

5. segm.org › NICE_gender_medicine_systematic_reviewNew Systematic Reviews of Puberty Blockers and Cross-Sex ...

   segm.org › NICE_gender_medicine_systematic_review

   • Cached

   Mar 31, 2021 · In 2020, the UK National Institute for Health and Care Excellence (NICE) undertook two systematic evidence reviews of the use of GnRH agonists (also known as "puberty blockers") and cross-sex hormones as treatments for gender dysphoric patients <18 years old. These reviews were commissioned by NHS England, as part of a review of gender dysphoria healthcare led by Dr Hilary Cass OBE.

6. cass.independent-review.uk › nice-evidence-reviewsNice Evidence Reviews – Cass Review

   cass.independent-review.uk › nice-evidence-reviews

   • Cached

   The evidence reviews were published in March 2021. Unfortunately, the available evidence was not deemed strong enough to form the basis of a policy position. National Institute for Health and Care Excellence (2020). Evidence Review: Gonadotrophin Releasing Hormone Analogues for Children and Adolescents with Gender Dysphoria.

7. thebms.org.uk › wp-content › uploadsBMS & WHC’s 2020 recommendations on hormone replacement ...

   thebms.org.uk › wp-content › uploads

   MS & WHC’s 2020 recommendations on hormone replacement therapy in menopausal womenThe British Menopause Society (. MS) is the specialist authority for menopause and post reproductive health in the UK. The BMS educates, informs and guides healthcare professionals, working in both. primary and secondary care, on menopause and all aspects of ...

8. People also ask

   Are gender-affirming hormones a cost-effective treatment for gender dysphoria?

   • The review found no evidence of cost-effectiveness of treatment. NICE also reviewed the evidence base for gender-affirming hormones - sometimes known as cross-sex hormones. These can be given to young people with gender dysphoria from age 16 in the NHS.

   Evidence for puberty blockers use very low, says NICE - BBC

   www.bbc.com/news/health-56601386

   See all results for this question

   Can hormone treatment change a'regression-to-the-mean' score?

   • The reviewers noted that “a fundamental limitation of all the uncontrolled studies in this review is that any changes in scores from baseline to follow-up could be attributed to a regression-to-the-mean,” rather than the beneficial effects of hormone treatment.

   New Systematic Reviews of Puberty Blockers and Cross-Sex Hormones

   segm.org/NICE_gender_medicine_systematic_review_finds_poor_quality_evidence

   See all results for this question

   When should a non-hysterectomised woman take HRT?

   • aged to use HRT at least until the average age of the menopause.Routes and regimens Non-hysterectomised women require progestogen (administered for 12-14 days in a sequential regimen and daily in a continuous combined regimen) to minimise the risk of endom

   BMS & WHC’s 2020 recommendations on hormone replacement therap…

   thebms.org.uk/wp-content/uploads/2023/10/02-BMS-ConsensusStatement-BMS-WHC-2020-Recommendations-on-HRT-in-menopausal-women-SEPT2023-A.pdf

   See all results for this question

   Can a cyclical HRT regimen be changed?

   • duled bleeding, the HRT regimen could be changed to a cyclical intake of progestogen.For cyclical HRT regimens, the dose of progestogen could be increased (e.g. micronised progesterone 300 mg for 12 days a month instead of 200 mg) or increase duration of progestogen intake (can

   BMS & WHC’s 2020 recommendations on hormone replacement therap…

   thebms.org.uk/wp-content/uploads/2023/10/02-BMS-ConsensusStatement-BMS-WHC-2020-Recommendations-on-HRT-in-menopausal-women-SEPT2023-A.pdf

   See all results for this question

   How long should hormone replacement therapy (HRT) be delivered?

   • Within Hormone Replacement Therapy (HRT) regimens, this should be delivered for at least the same duration as that produced during the luteal phase of the monthly cycle and in the recommended doses to protect against the risk of endometrial hyperplasia and endometrial cancer. 1 – 3

   British Menopause Society tools for clinicians: Progestogens and

   journals.sagepub.com/doi/full/10.1177/20533691211058030

   See all results for this question

   Is there a roadblock to gender-affirming care?

   • The NICE review of puberty blockers has been favorably commented on by the Society for Evidence-Based Gender Medicine (SEGM), who have used it to argue against gender-affirming care. Opponents to gender-affirming care, such as Stephen B. Levine, have also cited this source.

   conclusions not so nice: a critical analysis of the nice evidence

   sciencebasedmedicine.org/a-critical-look-at-the-nice-review/

   See all results for this question

9. journals.sagepub.com › doi › fullBritish Menopause Society tools for clinicians: Progestogens ...

   journals.sagepub.com › doi › full

   Nov 27, 2021 · A systematic review by Stute et al. (2016) assessed the impact of micronized progesterone on the endometrium. Forty studies were included in the systematic review and it concluded that oral micronized progesterone provides endometrial protection if applied sequentially for 12–14 days/month in a dose of 200 mg/day for up to five years. 18